Larotrectinib, a highly selective inhibitor of all three tropomyosin receptor
kinase (TRK) proteins, was recently shown to have marked and
sustained antitumor
activity in patients with TRK fusion — positive cancers, according to an analysis of three phase I and II cohorts.
Disruption of Autophagy at the Maturation Step by the Carcinogen Lindane Is Associated with the
Sustained Mitogen - Activated Protein
Kinase / Extracellular Signal — Regulated
Kinase Activity